Treace Medical Concepts (TMCI) Competitors $5.79 -0.06 (-1.03%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$5.84 +0.05 (+0.85%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TMCI vs. AORT, CDRE, ESTA, TNDM, FNA, BLFS, LQDA, SSII, PLSE, and INMDShould you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include Artivion (AORT), Cadre (CDRE), Establishment Labs (ESTA), Tandem Diabetes Care (TNDM), Paragon 28 (FNA), BioLife Solutions (BLFS), Liquidia Technologies (LQDA), SS Innovations International (SSII), Pulse Biosciences (PLSE), and InMode (INMD). These companies are all part of the "medical equipment" industry. Treace Medical Concepts vs. Its Competitors Artivion Cadre Establishment Labs Tandem Diabetes Care Paragon 28 BioLife Solutions Liquidia Technologies SS Innovations International Pulse Biosciences InMode Treace Medical Concepts (NASDAQ:TMCI) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership. Is TMCI or AORT more profitable? Artivion has a net margin of -5.49% compared to Treace Medical Concepts' net margin of -25.14%. Artivion's return on equity of 3.63% beat Treace Medical Concepts' return on equity.Company Net Margins Return on Equity Return on Assets Treace Medical Concepts-25.14% -48.69% -24.59% Artivion -5.49%3.63%1.34% Do institutionals & insiders believe in TMCI or AORT? 84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 27.7% of Treace Medical Concepts shares are owned by company insiders. Comparatively, 7.6% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, TMCI or AORT? Artivion has higher revenue and earnings than Treace Medical Concepts. Artivion is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTreace Medical Concepts$209.36M1.74-$55.74M-$0.85-6.81Artivion$388.54M3.39-$13.36M-$0.50-61.69 Which has more volatility & risk, TMCI or AORT? Treace Medical Concepts has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Do analysts prefer TMCI or AORT? Treace Medical Concepts currently has a consensus price target of $10.52, indicating a potential upside of 81.64%. Artivion has a consensus price target of $32.40, indicating a potential upside of 5.03%. Given Treace Medical Concepts' higher probable upside, analysts clearly believe Treace Medical Concepts is more favorable than Artivion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Treace Medical Concepts 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Artivion 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media prefer TMCI or AORT? In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 1 articles in the media. Treace Medical Concepts' average media sentiment score of 1.77 beat Artivion's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryArtivion beats Treace Medical Concepts on 12 of the 16 factors compared between the two stocks. Get Treace Medical Concepts News Delivered to You Automatically Sign up to receive the latest news and ratings for TMCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TMCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TMCI vs. The Competition Export to ExcelMetricTreace Medical ConceptsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$367.91M$6.58B$5.56B$9.34BDividend YieldN/A1.28%3.80%4.06%P/E Ratio-6.8125.4028.0819.86Price / Sales1.7463.96433.4499.92Price / CashN/A20.4535.8457.94Price / Book3.204.688.255.67Net Income-$55.74M$174.76M$3.24B$257.80M7 Day Performance-3.50%2.05%1.43%1.87%1 Month Performance6.04%3.96%8.02%10.92%1 Year Performance-26.62%5.13%30.07%18.51% Treace Medical Concepts Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TMCITreace Medical Concepts2.8646 of 5 stars$5.79-1.0%$10.52+81.6%-31.4%$367.91M$209.36M-6.81250AORTArtivion2.0208 of 5 stars$30.22-1.6%$32.40+7.2%+10.6%$1.31B$388.54M-60.441,600CDRECadre2.9874 of 5 stars$31.84-1.2%$37.50+17.8%-13.8%$1.31B$567.56M33.522,284Positive NewsESTAEstablishment Labs2.2046 of 5 stars$46.11+5.9%$52.40+13.6%-10.7%$1.26B$166.02M-14.871,018Positive NewsAnalyst ForecastTNDMTandem Diabetes Care4.3359 of 5 stars$16.25-3.2%$33.43+105.7%-66.3%$1.12B$982.95M-5.852,650Analyst RevisionFNAParagon 28N/A$13.11+0.1%$12.75-2.7%+54.0%$1.10B$256.18M-17.71343,000High Trading VolumeBLFSBioLife Solutions2.4013 of 5 stars$21.81-4.5%$31.17+42.9%-4.8%$1.08B$82.25M-75.20440LQDALiquidia Technologies3.248 of 5 stars$12.45+2.1%$26.89+116.0%+28.8%$1.04B$14M-7.8850Insider TradeSSIISS Innovations InternationalN/A$5.27-1.3%N/AN/A$1.03B$20.65M0.004PLSEPulse Biosciences3.7888 of 5 stars$15.81+3.3%$22.00+39.2%-4.5%$1.03B$700K0.00140INMDInMode4.1041 of 5 stars$15.10-0.4%$18.54+22.8%-24.7%$958.25M$392.41M6.48480 Related Companies and Tools Related Companies Artivion Alternatives Cadre Alternatives Establishment Labs Alternatives Tandem Diabetes Care Alternatives Paragon 28 Alternatives BioLife Solutions Alternatives Liquidia Technologies Alternatives SS Innovations International Alternatives Pulse Biosciences Alternatives InMode Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TMCI) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Treace Medical Concepts With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
